Therapeutic depth
Expand curative options across oncology, neurodegeneration, cardiometabolic disease, and autoimmunity.
Track 1
Make all diseases curable
LEV requires collapsing disease burden. This track turns major diseases from long-term damage pathways into curable or durably manageable states.
What needs to improve
Translational speed
Shorten lab-to-clinic cycles using adaptive trials, better endpoints, and faster manufacturing handoff.
Access reliability
Progress only counts at population scale; outcomes depend on affordability, delivery, and adherence.
Possible milestones
Research goals, not forecasts or a promised timeline.
Step 1
More high-burden diseases become treatable
Incremental survival gains from stronger standard-of-care combinations.
Step 2
Durable remission becomes common
Higher cure-like outcomes with biomarker-guided precision treatment paths.
Step 3
Curability baseline shifts
Disease categories that once limited lifespan become routinely reversible.
Main risks
- Trial design bottlenecks and weak cross-study comparability.
- Manufacturing limits for advanced biologics and cell therapies.
- Access inequality between countries and care systems.